Acalabrutinib: a bruton tyrosine kinase inhibitor for the treatment of chronic lymphocytic leukemia
A Wolska-Washer, T Robak - Expert Review of Hematology, 2022 - Taylor & Francis
Introduction The first-in-class Bruton tyrosine kinase (BTK), ibrutinib, demonstrated
remarkable activity in chronic lymphocytic leukemia (CLL). However, its toxicity profile …
remarkable activity in chronic lymphocytic leukemia (CLL). However, its toxicity profile …
Evidence-based management of chronic lymphocytic leukemia: consensus statements from the Gulf region
SH Alshemmari, MA Siddiqui, R Pandita… - Acta …, 2024 - karger.com
Introduction: Despite recent advances in diagnosis, prognostication, and treatment options,
chronic lymphocytic leukemia (CLL) is still a largely incurable disease. New concepts on …
chronic lymphocytic leukemia (CLL) is still a largely incurable disease. New concepts on …
Immunogenicity of a third dose of the BNT162b2 COVID-19 vaccine in patients with CLL: effects on treatment selection
PT Diamantopoulos, CN Kontandreopoulou… - Annals of …, 2022 - Springer
Patients with chronic lymphocytic leukemia (CLL) show suboptimal responses to the
vaccines against SARS-CoV-2; it has been shown though that a booster dose of the …
vaccines against SARS-CoV-2; it has been shown though that a booster dose of the …
The Disease Influenced Vaccine Acceptance Scale-Six (DIVAS-6): Validation of a Measure to Assess Disease-Related COVID-19 Vaccine Attitudes and Concerns
Patients with underlying comorbidities are particularly vulnerable to poor outcomes from
SARS-CoV-2 infection. Despite the context-specific nature of vaccine hesitancy, there are …
SARS-CoV-2 infection. Despite the context-specific nature of vaccine hesitancy, there are …
Brief research report: anti-SARS-CoV-2 immunity in long lasting responders to cancer immunotherapy through mrna-based COVID-19 vaccination
M Sisteré-Oró, DDJ Wortmann, N Andrade… - Frontiers in …, 2022 - frontiersin.org
Cancer patients (CPs) have been identified as particularly vulnerable to SARS-CoV-2
infection, and therefore are a priority group for receiving COVID-19 vaccination. From the …
infection, and therefore are a priority group for receiving COVID-19 vaccination. From the …
Management of chronic lymphocytic leukemia in Italy during a one year of the COVID‐19 pandemic and at the start of the vaccination program. A Campus CLL report
A Cuneo, GM Rigolin, M Coscia… - Hematological …, 2021 - Wiley Online Library
Twelve months after the outbreak of COVID‐19, the Campus CLL network that involves
hematology centers throughout Italy completed a survey (Tables 1 and 2) aimed at collecting …
hematology centers throughout Italy completed a survey (Tables 1 and 2) aimed at collecting …
Applicability of probabilistic graphical models for early detection of SARS-CoV-2 reactive antibodies after SARS-CoV-2 vaccination in hematological patients
JL Piñana, P Rodríguez-Belenguer, D Caballero… - Annals of …, 2022 - Springer
Prior studies of antibody response after full SARS-CoV-2 vaccination in hematological
patients have confirmed lower antibody levels compared to the general population …
patients have confirmed lower antibody levels compared to the general population …
Immunogenicity of COVID-19 vaccinations in hematological patients: 6-month follow-up and evaluation of a 3rd vaccination
L Schubert, M Koblischke, L Schneider, E Porpaczy… - Cancers, 2022 - mdpi.com
Simple Summary Here we confirm lower humoral and cellular responses in hematological
patients compared with controls and highlight the response in risk-groups such as CAR-T …
patients compared with controls and highlight the response in risk-groups such as CAR-T …
Safety and immunogenicity of the BNT162b2 mRNA Covid-19 vaccine in patients with chronic lymphocytic leukemia: a prospective study
PT Diamantopoulos, C Stafylidis… - Therapeutic …, 2022 - journals.sagepub.com
Introduction: Immunization of patients with chronic lymphocytic leukemia (CLL) with vaccines
against several infectious diseases has proven insufficient. Data on seroconversion of …
against several infectious diseases has proven insufficient. Data on seroconversion of …
Coronavirus-Specific Antibody and T Cell Responses Developed after Sputnik V Vaccination in Patients with Chronic Lymphocytic Leukemia
AA Komissarov, M Kislova, IA Molodtsov… - International Journal of …, 2022 - mdpi.com
The clinical course of the new coronavirus disease 2019 (COVID-19) has shown that
patients with chronic lymphocytic leukemia (CLL) are characterized by a high mortality rate …
patients with chronic lymphocytic leukemia (CLL) are characterized by a high mortality rate …